Usana

USANA, a US-headquartered company in the Pharmaceutical Preparation Manufacturing industry, reported approximately 1.39 million kg CO2e in Scope 1 emissions and 8.26 million kg CO2e in Scope 2 (market-based) emissions for 2025. Their total Scope 1 and 2 (market-based) emissions for 2025 were approximately 9.66 million kg CO2e.

In 2024, USANA's Scope 1 emissions were approximately 2.69 million kg CO2e, and Scope 2 (market-based) emissions were about 9.09 million kg CO2e, leading to total Scope 1 and 2 (market-based) emissions of around 11.27 million kg CO2e. For 2023, the company reported Scope 1 emissions of approximately 4.55 million kg CO2e and Scope 2 (market-based) emissions of about 9.12 million kg CO2e, with total Scope 1 and 2 (market-based) emissions reaching approximately 13.67 million kg CO2e.

Looking back, in 2022, USANA's Scope 1 emissions were approximately 4.11 million kg CO2e and Scope 2 emissions were about 11.05 million kg CO2e, with a combined Scope 1 and 2 total of approximately 15.17 million kg CO2e. In 2021, Scope 1 emissions were roughly 60,330 kg CO2e and Scope 2 emissions were about 3.68 million kg CO2e, resulting in total Scope 1 and 2 emissions of approximately 3.74 million kg CO2e. For 2020, USANA disclosed Scope 1 emissions of approximately 36,400 kg CO2e and Scope 2 emissions of about 3.46 million kg CO2e, with total Scope 1 and 2 emissions around 3.5 million kg CO2e.

USANA has disclosed Scope 1 and 2 emissions for all reported years but has not disclosed any Scope 3 emissions data. The company has not publicly reported any specific reduction targets, such as those validated by the Science Based Targets initiative (SBTi), nor any climate pledges. All reported emissions data and performance information are directly from USANA Health Sciences, Inc.